MML Investment Services Llc increased the percentage of Astrazeneca PLC (NASDAQ: AZN) that it owned by 22.1% during the third quarter, as stated in the most recent Form 13F filing that the company had with the SEC.

The corporation has 132,383 shares of its Stock in its possession after purchasing an additional 23,960 shares throughout the period in question, bringing the total to 132,383.

MML Investment Services LLC disclosed to the Securities and Exchange Commission in their most recent filing that the value of their holdings in AstraZeneca was $7,260,000.

Several institutional investors and other hedge funds recently altered the proportion of the company’s stock they owned in response to recent market events.

During the second quarter, FMR LLC added a total of 48.3% more shares of AstraZeneca to its holdings.

After completing these acquisitions, FMR LLC now holds 25,530,755 shares of the company’s stock, with an estimated current market value of $1,686,816,000.

During this period, the company also purchased an additional 8,319,805 shares, bringing the total number of shares it held to 8,319,805.

During the second quarter, GQG Partners LLC achieved a 2.4% increase in the proportion of AstraZeneca stock it owned. GQG Partners LLC now has 18,715,660 shares of the company’s stock, which has a value of $1,237,398,000 after purchasing an additional 434,979 shares during the period in question. Franklin Resources INC added 11.2% more shares of AstraZeneca to its portfolio over the second quarter. Franklin Resources INC now directly owns 17,096,147 shares after making an additional purchase of 1,718,792 shares during the most recent fiscal quarter.

The value of these shares on the market currently is $1,129,543,000.

A 22.0% increase in the proportion of AstraZeneca stock that BlackRock INC owns was accomplished during the first three months of 2018.

BlackRock INC now has 7,466,492 shares after purchasing an additional 1,343,939 in the most recent quarter.

The company’s shares are currently valued at a combined total of $495,328 because BlackRock INC And finally, during the second quarter, Renaissance Technologies LLC witnessed a rise of 28.4 percentage points in the quantity of AstraZeneca stock that it held. Renaissance Technologies LLC is the current owner of the company.

This entity currently holds 5,859,072 shares with a combined value of $387,109,000.

Institutional investors currently own 16.42% of the company’s shares; during the quarter, they increased their holdings of these shares by increasing their holdings of these shares by purchasing an additional 1,297,244 shares, bringing the total value of their stock holdings to $387,109,000.
AZN has been in touch with several different brokerage firms. JPMorgan Chase & Co announced in a research note made public on Tuesday, January 3, that they have increased the price target they have set for AstraZeneca shares.

The new price target is £135 ($162.57), an increase from the previous price target of £125 ($150.53). UBS Group increased their price target for AstraZeneca in a research report published on Tuesday.

The new price target is £119 ($143.30), increasing from £101 ($121.63).

TheStreet upgraded their previous rating of AstraZeneca from a “c” to an “a” after the company was the subject of a research study released on Monday, December 5.

In a research report made public on Thursday, December 15, Deutsche Bank Aktiengesellschaft raised their price objective on AstraZeneca shares from £120 ($144.51) to £130 ($156.55), putting the previous price objective at £120.

Berenberg Bank increased their target price on AstraZeneca shares from GBX 118 ($1.42) to GBX 126 ($1.52) in a research note published on Wednesday, January 18.

This was the last and most significant ascent of the mountain. Six research analysts have given the company a “buy” recommendation, four research analysts have given the company a “hold” recommendation, and one research analyst has given the company a “sell” recommendation.

According to data from Bloomberg.com, the company is currently rated as having a “Hold” status and has an average price target of $9,749.60.
When trading on AZN began on Thursday, the stock price was $68.85.

The price of AstraZeneca PLC has ranged from $52.65 to $72.12 over the past year, with a low of $52.65 and a high of $72.12.

The stock’s simple moving average over the past 50 days is $68.12, and its simple moving average over the past 200 days is $62.85.

There are a variety of financial ratios, some of which include a debt-to-equity ratio of 0.62, a current ratio of 0.86, and a quick ratio of 0.68.

The company has a beta value of 0.51 and PE ratios of 64.35, 1.28, and 1.28.

Its market capitalization is currently sitting at $213.41 billion at the moment. Key metrics for the company include these numbers.

The business recently made a public announcement concerning a semi-annual dividend, which is planned to be distributed on March 27 of this year.

The post MML Investors Services LLC Increases Its Position in AstraZeneca PLC (NASDAQ:AZN) appeared first on Best Stocks.